Cargando…

Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women

OBJECTIVES: To evaluate and compare the efficacy and safety of the combination of raloxifene and alendronate with those of monotherapies in elderly women with osteoporosis. METHODS: Sixty-two postmenopausal women (mean age 63.5 ± 0.5 years) attending gynecologic osteoporosis clinics with established...

Descripción completa

Detalles Bibliográficos
Autores principales:	Um, Mi Jung, Cho, Eun A, Jung, Hyuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Menopause 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432468/ https://www.ncbi.nlm.nih.gov/pubmed/28523260 http://dx.doi.org/10.6118/jmm.2017.23.1.56

Ejemplares similares

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2008)

Effects of the Combination Treatment of Raloxifene and Alendronate on the Biomechanical Properties of Vertebral Bone
por: Diab, Tamim, et al.
Publicado: (2011)

Alendronate and Raloxifene Therapy in the Early Period after Hip Fracture
por: Ohishi, Tsuyoshi, et al.
Publicado: (2011)

Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
por: Foster, Shonda A, et al.
Publicado: (2013)

Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model
por: Allen, Matthew R., et al.
Publicado: (2017)

Effect of aerobic exercise and raloxifene combination therapy on senile osteoporosis
por: Zhao, Chengjin, et al.
Publicado: (2016)

Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density
por: Cho, Young Hwa, et al.
Publicado: (2016)

Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy
por: Mullins, C. Daniel, et al.
Publicado: (2003)

Erratum to: Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density
por: Cho, Young Hwa, et al.
Publicado: (2017)

Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2005)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

A Nationwide Study on the Incidence of Breast Cancer in Korean Women with Osteoporosis Receiving Raloxifene Treatment
por: Lee, Jihyoun, et al.
Publicado: (2021)

Raloxifene/Vitamin D Combination Therapy vs. Raloxifene Monotherapy on Serum 25-Hydroxy-Vitamin D Level among Postmenopausal Women with Osteoporosis or Osteopenia: A Randomized Controlled Trial
por: Lee, You-Bin, et al.
Publicado: (2022)

Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
por: Bitto, A, et al.
Publicado: (2008)

Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
por: Lin, Tiao, et al.
Publicado: (2014)

Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model
por: Muraleva, Natalya A., et al.
Publicado: (2012)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment
por: Nagai, Noriaki, et al.
Publicado: (2018)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
por: Khanizadeh, Fatemeh, et al.
Publicado: (2018)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis
por: Suh, Hee-Won, et al.
Publicado: (2012)

Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2009)

Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis
por: Islander, Ulrika, et al.
Publicado: (2011)

Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single
por: Shin, Chang Jin, et al.
Publicado: (2016)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Retraction: Paper “Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis” by Iwamoto J, et al. [Yonsei Med J 2008;49(1):119-128]
Publicado: (2018)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

An Observational Study to Assess the Safety and Efficacy on Quality of Life and Patient Satisfaction With Raloxifene/Cholecalciferol Combination Therapy in Postmenopausal Women Requiring Prevention or Treatment for Osteoporosis
por: Chung, Yoon-Sok, et al.
Publicado: (2021)

Enhanced osteogenic differentiation of alendronate-conjugated nanodiamonds for potential osteoporosis treatment
por: Ahn, Guk Young, et al.
Publicado: (2021)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus
por: Xiong, Zhencheng, et al.
Publicado: (2022)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

A critical review of brand and generic alendronate for the treatment of osteoporosis
por: Brown, Jacques P, et al.
Publicado: (2013)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women
por: Lee, Dong-Yun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d3oc18kcrijjvj2ri6fml911k0